Cohance Lifesciences Quarterly Results for Trading Insights
In Sept 2025, Cohance Lifesciences (COHANCE) reported revenue ₹571 Cr and net profit ₹66 Cr — revenue -7.9% YoY. For annual financials, live price and key ratios, visit Cohance Lifesciences screener.
COHANCE Quarterly Results — Revenue, Profit & EPS Highlights
Cohance Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Cohance Lifesciences stock price data download to track price trends across different timeframes.
- Revenue of ₹571 Cr in Sept 2025 (-33.1% vs Mar 2025, -7.9% vs Sept 2024)
- Net Profit of ₹66 Cr in Sept 2025 (-43.6% vs Mar 2025, -52.2% vs Sept 2024)
- EBITDA of ₹137 Cr in Sept 2025 (-39.4% vs Mar 2025)
- Operating Margin of 22.0% in Sept 2025 (-3.0pp vs Mar 2025)
- Earnings Per Share of ₹1.94 in Sept 2025 (-38.6% vs Mar 2025)
Cohance Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
COHANCE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 571 | 853 | 564 | 551 | 620 | -33.1% | -7.9% |
| Net Profit (₹ Cr) | 66 | 117 | 46 | 29 | 138 | - | - |
| EBITDA (₹ Cr) | 137 | 226 | 118 | 97 | 222 | - | - |
| EPS (₹) | 1.94 | 3.16 | 1.28 | 0.96 | 3.63 | - | - |
| Operating Margin (%) | 22.0% | 25.0% | 19.0% | 17.0% | 34.0% | - | - |
COHANCE Share Price Trend — 1-Year Movement Across Quarterly Results
Cohance Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with COHANCE stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
COHANCE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cohance Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1878.2 | 14,875 | 3,125 | +10.8% | - | 21.0% | 144.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6760.5 | 2,860 | 689 | +7.1% | - | 24.1% | 260.3 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹149,048.00 Cr | 4405.7 | 3,219 | 591 | +11.3% | - | 18.4% | 251.2 |
|
Cipla
Mar 2026 |
₹116,053.85 Cr | 1432.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 208.5 |
|
Dr Reddys Laborator…
Mar 2026 |
₹108,804.06 Cr | 1336.7 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 504.4 |
All amounts in ₹ Crores